Balaxi Pharmaceuticals Receives WHO-GMP Certification For Jadcherla Formulation Facility

Balaxi received WHO-GMP certification for its Jadcherla formulation facility, valid through August 2029, and has commenced manufacturing initially approved products. Additional product approvals remain pending, with progressive portfolio expansion planned for international markets. Context: begins the facility’s commercial ramp.